SAN DIEGO--(BUSINESS WIRE)--Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) today announced that Scott M. Freeman, M.D., has joined the Company in the newly created position of Chief Medical Officer. As Chief Medical Officer, Dr. Freeman will be responsible for all clinical development programs and activities of the Company. Dr. Freeman brings to Hollis-Eden a strong background in strategic clinical drug development at a time when the Company has embarked on an aggressive development program with next-generation drug candidates for metabolic disorders, autoimmune conditions and cancers.
